- Home
- HSPO vs ETON Comparison
HSPO vs ETON Comparison
Compare HSPO & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSPO
- ETON
- Stock Information
- Founded
- HSPO 2014
- ETON 2017
- Country
- HSPO United States
- ETON United States
- Employees
- HSPO N/A
- ETON N/A
- Industry
- HSPO Blank Checks
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- HSPO Finance
- ETON Health Care
- Exchange
- HSPO Nasdaq
- ETON Nasdaq
- Market Cap
- HSPO 87.7M
- ETON 199.5M
- IPO Year
- HSPO 2022
- ETON 2018
- Fundamental
- Price
- HSPO $11.25
- ETON $8.77
- Analyst Decision
- HSPO
- ETON Strong Buy
- Analyst Count
- HSPO 0
- ETON 3
- Target Price
- HSPO N/A
- ETON $12.00
- AVG Volume (30 Days)
- HSPO 27.4K
- ETON 214.1K
- Earning Date
- HSPO 01-01-0001
- ETON 11-11-2024
- Dividend Yield
- HSPO N/A
- ETON N/A
- EPS Growth
- HSPO N/A
- ETON N/A
- EPS
- HSPO 0.33
- ETON N/A
- Revenue
- HSPO N/A
- ETON $31,381,000.00
- Revenue This Year
- HSPO N/A
- ETON $19.61
- Revenue Next Year
- HSPO N/A
- ETON $35.39
- P/E Ratio
- HSPO $34.26
- ETON N/A
- Revenue Growth
- HSPO N/A
- ETON 8.14
- 52 Week Low
- HSPO $10.60
- ETON $3.03
- 52 Week High
- HSPO $11.25
- ETON $8.66
- Technical
- Relative Strength Index (RSI)
- HSPO 69.42
- ETON 76.07
- Support Level
- HSPO $11.17
- ETON $7.58
- Resistance Level
- HSPO $11.25
- ETON $8.66
- Average True Range (ATR)
- HSPO 0.00
- ETON 0.42
- MACD
- HSPO 0.00
- ETON -0.07
- Stochastic Oscillator
- HSPO 100.00
- ETON 91.49
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.